NASDAQ: TRVI Trevi Therapeutics, Inc. 10-K

Trevi reports positive Phase 2b results, FDA alignment on two Phase 3 trials starting Q2 2026

Filed March 17, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 18, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TRVI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.